These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16650397)

  • 1. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
    Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
    Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer.
    Tsushima H; Ito N; Tamura S; Matsuda Y; Inada M; Yabuuchi I; Imai Y; Nagashima R; Misawa H; Takeda H; Matsuzawa Y; Kawata S
    Clin Cancer Res; 2001 May; 7(5):1258-62. PubMed ID: 11350892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
    Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
    Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.
    Wakefield LM; Letterio JJ; Chen T; Danielpour D; Allison RS; Pai LH; Denicoff AM; Noone MH; Cowan KH; O'Shaughnessy JA
    Clin Cancer Res; 1995 Jan; 1(1):129-36. PubMed ID: 9815895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
    Sakaguchi K; Kitano M; Nishimura M; Senoh T; Ohta T; Terao M; Shinji N; Koide N; Tsuji T
    Hepatogastroenterology; 2004; 51(60):1780-3. PubMed ID: 15532825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
    Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
    Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer.
    Lin Y; Kikuchi S; Obata Y; Yagyu K;
    J Gastroenterol Hepatol; 2006 Feb; 21(2):432-7. PubMed ID: 16509870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity.
    Murase T; Anscher MS; Petros WP; Peters WP; Jirtle RL
    Bone Marrow Transplant; 1995 Feb; 15(2):173-8. PubMed ID: 7773206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
    Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
    Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma.
    Ghellal A; Li C; Hayes M; Byrne G; Bundred N; Kumar S
    Anticancer Res; 2000; 20(6B):4413-8. PubMed ID: 11205281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma.
    Okumoto K; Hattori E; Tamura K; Kiso S; Watanabe H; Saito K; Saito T; Togashi H; Kawata S
    Liver Int; 2004 Feb; 24(1):21-8. PubMed ID: 15101997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
    Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of recognition site between transforming growth factor-beta1 (TGF-beta1) and TGF beta receptor type II: possible implications in breast cancer.
    Ivanović V; Demajo M; Todorović-Raković N; Nikolić-Vukosavljević D; Nesković-Konstantinović Z; Krtolica K; Veljković V; Prljić J; Dimitrijević B
    Med Hypotheses; 2004; 62(5):727-32. PubMed ID: 15082097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
    Wolff JM; Fandel TH; Borchers H; Jakse G
    Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
    Gora-Tybor J; Blonski JZ; Robak T
    Mediators Inflamm; 2003 Jun; 12(3):167-71. PubMed ID: 12857600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum big endothelin-1 levels in female patients with breast cancer.
    Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
    Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.